Challenges in detecting disease modification in Parkinson's disease clinical trials

Parkinsonism and Related Disorders

Volumn 32, Issue , 2016, Pages 1-11

  Athauda, Dilan ^a   Foltynie, Thomas ^a  

^a NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN[1-42]; DEFERIPRONE; EXENDIN 4; GLUCOSYLCERAMIDASE; LEUCINE RICH REPEAT KINASE 2; LEVODOPA; PRAMIPEXOLE; RASAGILINE; SELEGILINE; TAU PROTEIN; TRASTUZUMAB; NEUROPROTECTIVE AGENT;

COHORT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; DRUG EFFICACY; DRUG HALF LIFE; EPIGENETICS; GBA GENE; GENE; GENE ACTIVITY; GENE MUTATION; HUMAN; LIMIT OF QUANTITATION; LONGITUDINAL STUDY; LRRK2 GENE; MILD COGNITIVE IMPAIRMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; ORTHOSTATIC HYPOTENSION; PARASOMNIA; PARKINSON DISEASE; PATHOPHYSIOLOGY; PATIENT SELECTION; PERSONALIZED MEDICINE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHENOTYPE; PINK1 GENE; POPULATION RESEARCH; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; UNIFIED PARKINSON DISEASE RATING SCALE; ANIMAL; CLINICAL TRIAL (TOPIC); COGNITIVE DEFECT; COMPLICATION;

ANIMALS; CLINICAL TRIALS AS TOPIC; COGNITION DISORDERS; HUMANS; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE;

EID: 84994744856     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2016.07.019     Document Type: Review

References (94)

1. [1] Olanow, C.W., Kieburtz, K., Schapira, A.H.V., Why have we failed to achieve neuroprotection in Parkinson's disease?. Ann. Neurol 64:Suppl. 2 (2008), S101–S110, 10.1002/ana.21461.
2. [2] Kieburtz, K., Olanow, C.W., Advances in clinical trials for movement disorders. Mov. Disord. 30 (2015), 1580–1587, 10.1002/mds.26371.
3. [3] Rascol, O., “Disease-modification” trials in Parkinson disease: target populations, endpoints and study design. Neurology 72 (2009), S51–S58, 10.1212/WNL.0b013e318199049e.
4. [4] Van der Schyf, C.J., Rational drug discovery design approaches for treating Parkinson's disease. Expert Opin. Drug Discov. 10 (2015), 713–741, 10.1517/17460441.2015.1041495.
5. [5] Jin, G., Wong, S.T.C., Toward better drug repositioning: prioritizing and integrating existing methods into efficient pipelines. Drug Discov. Today 19 (2014), 637–644, 10.1016/j.drudis.2013.11.005.
6. [6] Rajput, A.H., Voll, A., Rajput, M.L., Robinson, C.A., Rajput, A., Course in Parkinson disease subtypes: a 39-year clinicopathologic study. Neurology 73 (2009), 206–212, 10.1212/WNL.0b013e3181ae7af1.
7. [7] Rajput, A.H., Sitte, H.H., Rajput, A., Fenton, M.E., Pifl, C., Hornykiewicz, O., Globus pallidus dopamine and Parkinson motor subtypes: clinical and brain biochemical correlation. Neurology 70 (2008), 1403–1410, 10.1212/01.wnl.0000285082.18969.3a.
8. [8] Reinoso, G., Allen, J.C., Au, W.L., Seah, S.H., Tay, K.Y., Tan, L.C.S., Clinical evolution of Parkinson's disease and prognostic factors affecting motor progression: 9-year follow-up study. Eur. J. Neurol. 22 (2015), 457–463, 10.1111/ene.12476.
9. [9] Pagano, G., Ferrara, N., Brooks, D.J., Age at onset and Parkinson disease phenotype. Neurology, 2016, 10.1212/WNL.0000000000002461.
10. [10] Foltynie, T., Brayne, C., Barker, R.A., The heterogeneity of idiopathic Parkinson's disease. J. Neurol. 249 (2002), 138–145 http://www.ncbi.nlm.nih.gov/pubmed/11985378 (accessed 25.07.14).
11. [11] Fereshtehnejad, S., Romenets, S., Anang, J., et al. New clinical subtypes of parkinson disease and their longitudinal progression. JAMA Neurol. 72 (2015), E1–E11, 10.1001/jamaneurol.2015.0703.
12. [12] Velseboer, D.C., de Bie, R.M.A., Wieske, L., Evans, J.R., Mason, S.L., Foltynie, T., et al. Development and external validation of a prognostic model in newly diagnosed Parkinson disease. Neurology 86 (2016), 986–993, 10.1212/WNL.0000000000002437.
13. [13] Simuni, T., Caspell-Garcia, C., Coffey, C., Lasch, S., Tanner, C., Marek, K., How stable are Parkinson's disease subtypes in de novo patients: analysis of the PPMI cohort?. Park. Relat. Disord. 28 (2016), 62–67, 10.1016/j.parkreldis.2016.04.027.
14. [14] Kang, J.-H., Mollenhauer, B., Coffey, C.S., Toledo, J.B., Weintraub, D., Galasko, D.R., et al. CSF biomarkers associated with disease heterogeneity in early Parkinson's disease: the Parkinson's Progression Markers Initiative study – Springer. Acta Neuropathol., 2016 http://link.springer.com/article/10.1007/s00401-016-1552-2/fulltext.html#CR30 (accessed 27.04.16).
15. [15] Williams-Gray, C.H., Wijeyekoon, R., Yarnall, A.J., Lawson, R.A., Breen, D.P., Evans, J.R., et al. Serum immune markers and disease progression in an incident Parkinson's disease cohort (ICICLE-PD). Mov. Disord., 00, 2016, 10.1002/mds.26563 n/a–n/a.
16. [16] Corti, O., Fournier, M., Brice, A., Neurodegeneration in Parkinson's disease: genetics enlightens physiopathology. J. Neural Transm. Suppl., 2009, 215–221 http://www.ncbi.nlm.nih.gov/pubmed/20411780 (accessed 25.04.16).
17. [17] Pihlstrøm, L., Morset, K.R., Grimstad, E., Vitelli, V., A cumulative genetic risk score predicts motor progression in Parkinson's disease. Mov. Disord. 00 (2016), 1–8, 10.1002/mds.26505.
18. [18] Cooper, O., Seo, H., Andrabi, S., Guardia-Laguarta, C., Graziotto, J., Sundberg, M., et al. Pharmacological rescue of mitochondrial deficits in iPSC-derived neural cells from patients with familial Parkinson's disease. Sci. Transl. Med., 4, 2012, 10.1126/scitranslmed.3003985 141ra90.
19. [19] Rasool, M., Malik, A., Naseer, M.I., Manan, A., Ansari, S., Begum, I., et al. The role of epigenetics in personalized medicine: challenges and opportunities. BMC Med. Genomics, 8(Suppl. 1), 2015, S5, 10.1186/1755-8794-8-S1-S5.
20. [20] McNeill, A., Magalhaes, J., Shen, C., Chau, K.-Y., Hughes, D., Mehta, A., et al. Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells. Brain 137 (2014), 1481–1495, 10.1093/brain/awu020.
21. [21] Kordower, J.H., Olanow, C.W., Dodiya, H.B., Chu, Y., Beach, T.G., Adler, C.H., et al. Disease duration and the integrity of the nigrostriatal system in Parkinson's disease. Brain 136 (2013), 2419–2431, 10.1093/brain/awt192.
22. [22] Tolosa, E., Gaig, C., Santamaría, J., Compta, Y., Diagnosis and the premotor phase of Parkinson disease. Neurology 72 (2009), S12–S20, 10.1212/WNL.0b013e318198db11.
23. [23] Hilker, R., Schweitzer, K., Coburger, S., Ghaemi, M., Weisenbach, S., Jacobs, A.H., et al. Nonlinear progression of Parkinson disease as determined by serial positron emission tomographic imaging of striatal fluorodopa F 18 activity. Arch. Neurol. 62 (2005), 378–382, 10.1001/archneur.62.3.378.
24. [24] Noyce, A.J., Bestwick, J.P., Silveira-Moriyama, L., Hawkes, C.H., Giovannoni, G., Lees, A.J., et al. Meta-analysis of early nonmotor features and risk factors for Parkinson disease. Ann. Neurol. 72 (2012), 893–901, 10.1002/ana.23687.
25. [25] Noyce, A.J., Lees, A.J., Schrag, A.-E., The prediagnostic phase of Parkinson's disease. J. Neurol. Neurosurg. Psychiatry, 2016, 10.1136/jnnp-2015-311890 jnnp–2015–311890.
26. [26] Salat, D., Noyce, A.J., Schrag, A., Tolosa, E., Challenges of modifying disease progression in prediagnostic Parkinson's disease. Lancet Neurol. 4422 (2016), 1–12, 10.1016/S1474-4422(16)00060-0.
27. [27] Keezer, M.R., Wolfson, C., Postuma, R.B., Age, gender, comorbidity, and the MDS-UPDRS: results from a population-based study. Neuroepidemiology 46 (2016), 222–227, 10.1159/000444021.
28. [28] Berg, D., Behnke, S., Seppi, K., Godau, J., Lerche, S., Mahlknecht, P., et al. Enlarged hyperechogenic substantia nigra as a risk marker for Parkinson's disease. Mov. Disord. 28 (2013), 216–219, 10.1002/mds.25192.
29. [29] Dehay, B., Targeting α-synuclein: therapeutic options. Mov. Disord., 2016 http://www.ncbi.nlm.nih.gov/pubmed/26926119 (accessed 26.04.16).
30. [30] Hashimoto, M., Hsu, L.J., Rockenstein, E., Takenouchi, T., Mallory, M., Masliah, E., alpha-Synuclein protects against oxidative stress via inactivation of the c-Jun N-terminal kinase stress-signaling pathway in neuronal cells. J. Biol. Chem. 277 (2002), 11465–11472, 10.1074/jbc.M111428200.
31. [31] Olanow, C.W., Hauser, R.A., Jankovic, J., Langston, W., Lang, A., Poewe, W., et al. A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): rationale, design, and baseline characteristics. Mov. Disord. 23 (2008), 2194–2201, 10.1002/mds.22218.
32. [32] Fahn, S., Oakes, D., Shoulson, I., Kieburtz, K., Rudolph, A., Lang, A., et al. Levodopa and the progression of Parkinson's disease. N. Engl. J. Med. 351 (2004), 2498–2508, 10.1056/NEJMoa033447.
33. [33] Olanow, C.W., Hauser, R.A., Gauger, L., Malapira, T., Koller, W., Hubble, J., et al. The effect of deprenyl and levodopa on the progression of Parkinson's disease. Ann. Neurol. 38 (1995), 771–777, 10.1002/ana.410380512.
34. [34] Hauser, R.A., Holford, N.H.G., Quantitative description of loss of clinical benefit following withdrawal of levodopa-carbidopa and bromocriptine in early Parkinson's disease. Mov. Disord. 17 (2002), 961–968, 10.1002/mds.10226.
35. [35] Mestre, T.A., Shah, P., Marras, C., Tomlinson, G., Lang, A.E., Another face of placebo: the lessebo effect in Parkinson disease: meta-analyses. Neurology 82 (2014), 1402–1409, 10.1212/WNL.0000000000000340.
36. [36] Liu-Seifert, H., Andersen, S.W., Lipkovich, I., Holdridge, K.C., Siemers, E., A novel approach to delayed-start analyses for demonstrating disease-modifying effects in Alzheimer's disease. PLoS One, 10, 2015, e0119632, 10.1371/journal.pone.0119632.
37. [37] Parkinson Study Group, A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. Arch. Neurol. 59 (2002), 1937–1943 http://www.ncbi.nlm.nih.gov/pubmed/12470183 (accessed 22.02.16).
38. [38] Schapira, A.H.V., McDermott, M.P., Barone, P., Comella, C.L., Albrecht, S., Hsu, H.H., et al. Pramipexole in patients with early Parkinson's disease (PROUD): a randomised delayed-start trial. Lancet. Neurol. 12 (2013), 747–755, 10.1016/S1474-4422(13)70117-0.
39. [39] Devos, D., Moreau, C., Devedjian, J.C., Kluza, J., Petrault, M., Laloux, C., et al. Targeting chelatable iron as a therapeutic modality in Parkinson's disease. Antioxid. Redox Signal. 21 (2014), 195–210, 10.1089/ars.2013.5593.
40. [40] Verschuur, C.V.M., Suwijn, S.R., Post, B., Dijkgraaf, M., Bloem, B.R., van Hilten, J.J., et al. Protocol of a randomised delayed-start double-blind placebo-controlled multi-centre trial for Levodopa in EArly Parkinson's disease: the LEAP-study. BMC Neurol., 15, 2015, 236, 10.1186/s12883-015-0491-1.
41. [41] Shulman, L.M., Gruber-Baldini, A.L., Anderson, K.E., Fishman, P.S., Reich, S.G., Weiner, W.J., The clinically important difference on the unified Parkinson's disease rating scale. Arch. Neurol. 67 (2010), 64–70, 10.1001/archneurol.2009.295.
42. [42] Schrag, A., Sampaio, C., Counsell, N., Poewe, W., Minimal clinically important change on the unified Parkinson's disease rating scale. Mov. Disord. 21 (2006), 1200–1207, 10.1002/mds.20914.
43. [43] Rascol, O., Defining a minimal clinically relevant difference for the unified Parkinson's rating scale: an important but still unmet need. Mov. Disord. 21 (2006), 1059–1061, 10.1002/mds.20913.
44. [44] Schwid, S.R., Cutter, G.R., Editorial CME Futility studies Spending a little to save a lot. Neurology 66 (2006), 626–627.
45. [45] Levin, B., The futility study–progress over the last decade. Contemp. Clin. Trials 45 (2015), 69–75, 10.1016/j.cct.2015.06.013.
46. [46] NINDS Exploratory Trials in Parkinson Disease (NET-PD) FS-ZONE Investigators, Pioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial. Lancet. Neurol. 14 (2015), 795–803, 10.1016/S1474-4422(15)00144-1.
47. [47] Parashos, S.A., Luo, S., Biglan, K.M., Bodis-Wollner, I., He, B., Liang, G.S., et al. Measuring disease progression in early parkinson disease: the National Institutes of Health Exploratory Trials in Parkinson Disease (NET-PD) experience. JAMA Neurol. 71 (2014), 710–716, 10.1001/jamaneurol.2014.391.
48. [48] Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson disease. Neurology 69 (2007), 1480–1490, 10.1212/01.wnl.0000277648.63931.c0.
49. [49] Lang, A.E., Melamed, E., Poewe, W., Rascol, O., Trial designs used to study neuroprotective therapy in Parkinson's disease. Mov. Disord. 28 (2013), 86–95, 10.1002/mds.24997.
50. [50] Aviles-Olmos, I., Dickson, J., Kefalopoulou, Z., Djamshidian, A., Ell, P., Soderlund, T., et al. Exenatide and the treatment of patients with Parkinson's disease. J. Clin. Investig., 123, 2013, 10.1172/JCI68295.2730.
51. [51] Aviles-Olmos, I., Dickson, J., Kefalopoulou, Z., Djamshidian, A., Kahan, J., Fmedsci, P.E., et al. Motor and cognitive advantages persist 12 Months After exenatide exposure in Parkinson's disease. J. Park. Dis., 2014, 10.3233/JPD-140364.
52. [52] Barker, R.A., Stacy, M., Brundin, P., A new approach to disease-modifying drug trials in Parkinson's disease. J. Clin. Investig. 123 (2013), 2364–2365, 10.1172/JCI69690.
53. [53] de la Fuente-Fernández, R., Stoessl, A.J., The placebo effect in Parkinson's disease. Trends Neurosci. 25 (2002), 302–306, 10.1016/S0166-2236(02)02181-1.
54. [54] Lidstone, S.C., Great expectations: the placebo effect in Parkinson's disease. Handb. Exp. Pharmacol. 225 (2014), 139–147, 10.1007/978-3-662-44519-8_8.
55. [55] Lang, A.E., Gill, S., Patel, N.K., Lozano, A., Nutt, J.G., Penn, R., et al. Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann. Neurol. 59 (2006), 459–466, 10.1002/ana.20737.
56. [56] Hutchinson, M., Gurney, S., Newson, R., GDNF in Parkinson disease: an object lesson in the tyranny of type II. J. Neurosci. Methods 163 (2007), 190–192, 10.1016/j.jneumeth.2006.06.015.
57. [57] Mcfadden, B., Heitzman-powell, L., Novel methods and technologies for 21st-century clinical trials: a review. JAMA Neurol. 8 (2015), 1699–1712, 10.1016/j.rasd.2014.08.015.Social.
58. [58] Ploeger, B.A., Holford, N.H.G., Washout and delayed start designs for identifying disease modifying effects in slowly progressive diseases using disease progression analysis. Pharm. Stat. 8 (2009), 225–238, 10.1002/pst.355.
59. [59] Björnsson, M.A., Friberg, L.E., Simonsson, U.S.H., Performance of nonlinear mixed effects models in the presence of informative dropout. AAPS J. 17 (2015), 245–255, 10.1208/s12248-014-9700-x.
60. [60] Siddiqui, O., Hung, H.M.J., O'Neill, R., MMRM vs. LOCF: a comprehensive comparison based on simulation study and 25 NDA datasets. J. Biopharm. Stat. 19 (2009), 227–246, 10.1080/10543400802609797.
61. [61] Olanow, C.W., Schapira, A.H.V., LeWitt, P.A., Kieburtz, K., Sauer, D., Olivieri, G., et al. TCH346 as a neuroprotective drug in Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol. 5 (2006), 1013–1020, 10.1016/S1474-4422(06)70602-0.
62. [62] Parashos, S.A., Swearingen, C.J., Biglan, K.M., Bodis-Wollner, I., Liang, G.S., Ross, G.W., et al. Determinants of the timing of symptomatic treatment in early Parkinson disease: the National Institutes of Health Exploratory Trials in Parkinson Disease (NET-PD) experience. Arch. Neurol. 66 (2009), 1099–1104, 10.1001/archneurol.2009.159.
63. [63] Ward, C.D., Does selegiline delay progression of Parkinson's disease? A critical re-evaluation of the DATATOP study. J. Neurol. Neurosurg. Psychiatr. 57 (1994), 217–220 http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1072455&tool=pmcentrez&rendertype=abstract (accessed 11.07.14).
64. [64] Kempster, P.A., O'Sullivan, S.S., Holton, J.L., Revesz, T., Lees, A.J., Relationships between age and late progression of Parkinson's disease: a clinico-pathological study. Brain 133 (2010), 1755–1762, 10.1093/brain/awq059.
65. [65] Williams-Gray, C.H., Mason, S.L., Evans, J.R., Foltynie, T., Brayne, C., Robbins, T.W., et al. The CamPaIGN study of Parkinson's disease: 10-year outlook in an incident population-based cohort. J. Neurol. Neurosurg. Psychiatr. 84 (2013), 1258–1264, 10.1136/jnnp-2013-305277.
66. [66] Evans, J., Disease-modifying therapy trials in PD: what are the issues?. ACNR 14:3 (2014), 6–8 http://www.acnr.co.uk/2014/08/disease-modifying-therapy-trials-in-pd-what-are-the-issues/ (accessed 29.08.14).
67. [67] McGhee, D., Parker, A., Fielding, S., Zajicek, J., Counsell, C., Using “dead or dependent” as an outcome measure in clinical trials in Parkinson's disease. J. Neurol. Neurosurg. Psychiatr. 86 (2015), 180–185, 10.1136/jnnp-2014-307703.
68. [68] Goetz, C.G., Tilley, B.C., Shaftman, S.R., Stebbins, G.T., Fahn, S., Martinez-Martin, P., et al. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov. Disord. 23 (2008), 2129–2170, 10.1002/mds.22340.
69. [69] Goetz, C.G., Stebbins, G.T., Tilley, B.C., Calibration of unified Parkinson's disease rating scale scores to Movement Disorder Society-unified Parkinson's disease rating scale scores. Mov. Disord. 27 (2012), 1239–1242, 10.1002/mds.25122.
70. [70] Williams, J., Mari, Z., Pontone, G., Bassett, S., Natural history of UPDRS motor scores in an observational Parkinson's disease cohort (S22.004). Neurology, 78, 2012, S22.004 http://www.neurology.org/content/78/1_Supplement/S22.004.short (accessed 15.04.16).
71. [71] Papapetropoulos, S.S., Patient diaries as a clinical endpoint in Parkinson's disease clinical trials. CNS Neurosci. Ther. 18 (2012), 380–387, 10.1111/j.1755-5949.2011.00253.x.
72. [72] Utsumi, H., Terashi, H., Ishimura, Y., Takazawa, T., Okuma, Y., Yoneyama, M., et al. How far do the complaints of patients with Parkinson's disease reflect motor fluctuation? Quantitative analysis using a portable gait rhythmogram. ISRN Neurol., 2012, 2012, 372030, 10.5402/2012/372030.
73. [73] Davidson, M.B., McGhee, D.J.M., Counsell, C.E., Comparison of patient rated treatment response with measured improvement in Parkinson's disease. J. Neurol. Neurosurg. Psychiatr. 83 (2012), 1001–1005, 10.1136/jnnp-2012-302741.
74. [74] McGhee, D., Parker, A., Fielding, S., Counsell, C., Which clinical measures are most appropriate for measuring disease progression in parkinson's disease?. J. Neurol. Neurosurg. Psychiatr., 84, 2013, 10.1136/jnnp-2013-306573.163 e2–e2.
75. [75] Brooks, D.J., Pavese, N., Imaging biomarkers in Parkinson's disease. Prog. Neurobiol. 95 (2011), 614–628, 10.1016/j.pneurobio.2011.08.009.
76. [76] Femminella, G.D., Edison, P., Evaluation of neuroprotective effect of glucagon-like peptide 1 analogs using neuroimaging. Alzheimers. Dement. 10 (2014), S55–S61, 10.1016/j.jalz.2013.12.012.
77. [77] Whone, A.L., Watts, R.L., Stoessl, A.J., Davis, M., Reske, S., Nahmias, C., et al. Slower progression of Parkinson's disease with ropinirole versus levodopa: the REAL-PET study. Ann. Neurol. 54 (2003), 93–101, 10.1002/ana.10609.
78. [78] Ravina, B., Eidelberg, D., Ahlskog, J.E., Albin, R.L., Brooks, D.J., Carbon, M., et al. The role of radiotracer imaging in Parkinson disease. Neurology 64 (2005), 208–215, 10.1212/01.WNL.0000149403.14458.7F.
79. [79] Freed, C.R., Greene, P.E., Breeze, R.E., Tsai, W.-Y., DuMouchel, W., Kao, R., et al. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N. Engl. J. Med. 344 (2001), 710–719, 10.1056/NEJM200103083441002.
80. [80] Andersen, A.D., Binzer, M., Stenager, E., Gramsbergen, J.B., Cerebrospinal fluid biomarkers for Parkinson's disease – a systematic review. Acta Neurol. Scand., 2016, 10.1111/ane.12590.
81. [81] Miller, D.B., O'Callaghan, J.P., Biomarkers of Parkinson's disease (Pd): present and future. Metabolism 64 (2014), S40–S46, 10.1016/j.metabol.2014.10.030.
82. [82] Bagchi, D.P., Yu, L., Perlmutter, J.S., Xu, J., Mach, R.H., Tu, Z., et al. Binding of the radioligand SIL23 to α-synuclein fibrils in Parkinson disease brain tissue establishes feasibility and screening approaches for developing a Parkinson disease imaging agent. PLoS One, 8, 2013, e55031, 10.1371/journal.pone.0055031.
83. [83] Mak, E., Su, L., Williams, G.B., Firbank, M.J., Lawson, R.A., Yarnall, A.J., et al. Baseline and longitudinal grey matter changes in newly diagnosed Parkinson's disease: ICICLE-PD study. Brain 138 (2015), 2974–2986, 10.1093/brain/awv211.
84. [84] Post, B., Merkus, M.P., de Bie, R.M.A., de Haan, R.J., Speelman, J.D., Unified Parkinson's disease rating scale motor examination: are ratings of nurses, residents in neurology, and movement disorders specialists interchangeable?. Mov. Disord. 20 (2005), 1577–1584, 10.1002/mds.20640.
85. [85] Newington, L., Metcalfe, A., Factors influencing recruitment to research: qualitative study of the experiences and perceptions of research teams. BMC Med. Res. Methodol., 14, 2014, 10, 10.1186/1471-2288-14-10.
86. [86] Kott, A., Swartz, J., Does rater experience influence UPDRS inter-rater reliability?. 16th Int. Congr. Park. Dis. Mov. Disord, 2012 https://www.bracketglobal.com/wp-content/uploads/DoesRaterExperienceInfluenceUPDRSInterRaterReliabilityMDS2012.pdf (accessed 20.04.16).
87. [87] Ossig, C., Wearable sensor-based objective assessment of motor symptoms in Parkinson's disease – Springer. J. Neural Transm., 2016 http://link.springer.com/article/10.1007/s00702-015-1439-8/fulltext.html (accessed 20.04.16).
88. [88] Arora, S., Venkataraman, V., Zhan, A., Donohue, S., Biglan, K.M., Dorsey, E.R., et al. Detecting and monitoring the symptoms of Parkinson's disease using smartphones: a pilot study. Park. Relat. Disord. 21 (2015), 650–653, 10.1016/j.parkreldis.2015.02.026.
89. [89] Abdolahi, A., Scoglio, N., Killoran, A., Dorsey, E.R., Biglan, K.M., Potential reliability and validity of a modified version of the Unified Parkinson's Disease Rating Scale that could be administered remotely. Park. Relat. Disord. 19 (2013), 218–221, 10.1016/j.parkreldis.2012.10.008.
90. [90] Oung, Q.W., Muthusamy, H., Lee, H.L., Basah, S.N., Yaacob, S., Sarillee, M., et al. Technologies for assessment of motor disorders in Parkinson's disease: a review. Sensors (Basel) 15 (2015), 21710–21745, 10.3390/s150921710.
91. [91] Tzallas, A.T., Tsipouras, M.G., Rigas, G., Tsalikakis, D.G., Karvounis, E.C., Chondrogiorgi, M., et al. PERFORM: a system for monitoring, assessment and management of patients with Parkinson's disease. Sensors (Basel) 14 (2014), 21329–21357, 10.3390/s141121329.
92. [92] Mera, T.O., Heldman, D.A., Espay, A.J., Payne, M., Giuffrida, J.P., Feasibility of home-based automated Parkinson's disease motor assessment. J. Neurosci. Methods 203 (2012), 152–156, 10.1016/j.jneumeth.2011.09.019.
93. [93] Dorsey, E.R., Venkataraman, V., Grana, M.J., Bull, M.T., George, B.P., Boyd, C.M., et al. Randomized controlled clinical trial of “virtual house calls” for Parkinson disease. JAMA Neurol. 70 (2013), 565–570, 10.1001/jamaneurol.2013.123.
94. [94] Heldman, D.A., Espay, A.J., LeWitt, P.A., Giuffrida, J.P., Clinician versus machine: reliability and responsiveness of motor endpoints in Parkinson's disease. Park. Relat. Disord. 20 (2014), 590–595, 10.1016/j.parkreldis.2014.02.022.